Loading...
•
Mar 31
Exact Sciences Q1 2025 Earnings Report
Exact Sciences reported first-quarter 2025 results with strong revenue growth and notable product launches.
Key Takeaways
Exact Sciences delivered solid Q1 2025 performance with 11% revenue growth, improved profitability metrics, and the launch of two key diagnostic products, despite continuing to report a net loss.
Revenue rose to $707 million, up 11% from the previous year.
Net loss narrowed to $101 million, or $0.54 per share.
Cologuard Plus and Oncodetect were successfully launched.
Adjusted EBITDA jumped 61% to $63 million.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
Exact Sciences raised its full-year 2025 revenue and adjusted EBITDA guidance based on Q1 momentum and product rollouts.
Positive Outlook
- Full-year revenue midpoint raised by $40 million.
- Adjusted EBITDA midpoint increased by $15 million.
- Screening revenue guidance midpoint increased by $37.5 million.
- On track for Cancerguard EX launch in H2 2025.
- Expected Medicare reimbursement for Oncodetect in Q2 2025.
Challenges Ahead
- Company continues to operate at a net loss.
- Free cash flow remained slightly negative.
- High operating expenses at $597 million.
- Ongoing restructuring and business transformation costs.
- Limited growth in Precision Oncology revenue (2%).
Revenue & Expenses
Visualization of income flow from segment revenue to net income